Invariant natural killer t cell-based therapy of autoimmune diseases

Current Immunology Reviews

Volumn 6, Issue 2, 2010, Pages 88-101

  Gabriel, Curtis L ^a   Wu, Lan ^a   Parekh, Vrajesh V ^a   van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

galactosylceramide; Autoimmunity; Cd1d; Glycolipids; Immunomodulation; Invariant natural killer t cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CELL MATURATION; CELL THERAPY; CELL TYPE; GRAVES DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NATURAL KILLER T CELL; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROIDITIS; UVEITIS;

EID: 77952520597     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510791111682     Document Type: Article

References (184)

1. Budd RC, Miescher GC, Howe RC, Lees RK, Bron C, MacDonald HR. Developmentally regulated expression of T cell receptor beta chain variable domains in immature thymocytes. J Exp Med 1987; 166: 577-82.
2. Fowlkes BJ, Kruisbeek AM, Ton-That H, et al. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 1987; 329: 251-4.
3. Ceredig R, Lynch F, Newman P. Phenotypic properties, interleukin 2 production, and developmental origin of a mature subpopulation of Lyt-2- L3T4- mouse thymocytes. Proc Natl Acad Sci USA 1987; 84: 8578-82.
4. Godfrey D, MacDonald H, Kronenberg M, Smyth M, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-7.
5. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol 1995; 7: 1157-61.
6. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995; 268: 863-5.
7. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR- mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
8. Van Kaer L. Alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005; 5: 31-42.
9. Barral D, Brenner M. CD1 antigen presentation: how it works. Nat Rev Immunol 2007 2007; 7: 929-41.
10. Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 2007; 19: 354-64.
11. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379-88.
12. Chiu YH, Jayawardena J, Weiss A, et al. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 1999; 189: 103-10.
13. Behar SM, Podrebarac TA, Roy CJ, Wang CR, Brenner MB. Diverse TCRs recognize murine CD1. J Immunol 1999; 162: 161-7.
14. Jahng A, Maricic I, Aguilera C, Cardell S, Halder R, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199: 947-57.
15. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 2007; 7: 505-18.
16. Wakao H. NKT cells: from totipotency to regenerative medicine. Arch Immunol Ther Exp (Warsz); 57: 117-28.
17. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
18. Wei DG, Lee H, Park SH, et al. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J Exp Med 2005; 202: 239-48.
19. Stanic A, De Silva A, Park J, et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci USA 2003; 100: 1849-54.
20. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Gröne HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 2007; 104: 5977-82.
21. Lazarevic V, Zullo AJ, Schweitzer MN, et al. The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells. Nat Immunol 2009; 10: 306-13.
22. Schwartzberg PL, Mueller KL, Qi H, Cannons JL. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 2009; 9: 39-46.
23. Nichols KE, Hom J, Gong SY, et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005; 11: 340-5.
24. Pasquier B, Yin L, Fondaneche MC, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005; 201: 695-701.
25. Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol 2005; 174: 3153-7.
26. Eberl G, Lowin-Kropf B, MacDonald HR. Cutting edge: NKT cell development is selectively impaired in Fyn- deficient mice. J Immunol 1999; 163: 4091-4.
27. Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999; 190: 1189-96.
28. Griewank K, Borowski C, Rietdijk S, et al. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 2007; 27: 751-62.
29. Mycko MP, Ferrero I, Wilson A, et al. Selective requirement for c-Myc at an early stage of V(alpha)14i NKT cell development. J Immunol 2009; 182: 4641-8.
30. Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 2008; 112: 4139-47.
31. Locci M, Draghici E, Marangoni F, et al. The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med 2009; 206: 735-42.
32. Savage AK, Constantinides MG, Han J, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008; 29: 391-403.
33. Kovalovsky D, Uche OU, Eladad S, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 2008; 9: 1055-64.
34. Gapin L. The making of NKT cells. Nat Immunol 2008; 9: 1009-11.
35. Silk JD, Salio M, Brown J, Jones EY, Cerundolo V. Structural and functional aspects of lipid binding by CD1 molecules. Annu Rev Cell Dev Biol 2008; 24: 369-95.
36. Wu L, Gabriel CL, Parekh VV, Van Kaer L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 2009; 73(6): 535-45
37. Joyce S, Van Kaer L. CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol 2003; 15: 95-104.
38. Kang SJ, Cresswell P. Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain. J Biol Chem 2002; 277: 44838-44.
39. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4: 1230-7.
40. Mattner J, Debord K, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525-9.
41. Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 2007; 178: 2706-13.
42. Sköld M, Xiong X, Illarionov P, Besra G, Behar S. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J Immunol 2005; 175: 3584-93.
43. Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007; 448: 44-9.
44. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 2004; 82: 315-22.
45. Wilson M, Johansson C, Olivares-Villagómez D, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100: 10913-8.
46. Parekh V, Wilson M, Olivares-Villagómez D, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115: 2572-83.
47. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9: 28-38.
48. Bezbradica JS, Stanic AK, Matsuki N, et al. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 2005; 174: 4696-705.
49. Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA 2005; 102: 1127-32.
50. Kim S, Lalani S, Parekh VV, Vincent TL, Wu L, Van Kaer L. Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. J Clin Invest 2008; 118: 2301-15.
51. Choi HJ, Xu H, Geng Y, Colmone A, Cho H, Wang CR. Bacterial infection alters the kinetics and function of iNKT cell responses. J Leukoc Biol 2008; 84: 1462-71.
52. Chiba A, Dascher CC, Besra GS, Brenner MB. Rapid NKT cell responses are self-terminating during the course of microbial infection. J Immunol 2008; 181: 2292-302.
53. Chang WS, Kim JY, Kim YJ, et al. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008; 181: 6707-10.
54. Parekh VV, Lalani S, Kim S, et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182: 2816-26.
55. Wang J, Cheng L, Wondimu Z, Swain M, Santamaria P, Yang Y. Cutting edge: CD28 engagement releases antigen-activated invariant NKT cells from the inhibitory effects of PD-1. J Immunol 2009; 182: 6644-7.
56. Silk JD, Salio M, Reddy BG, et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 2008; 180: 6452-6.
57. Crowe NY, Coquet JM, Berzins SP, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005; 202: 1279-88.
58. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002; 195: 637-41.
59. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195: 625-36.
60. Coquet JM, Chakravarti S, Kyparissoudis K, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci USA 2008; 105: 11287-92.
61. Michel ML, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007; 204: 995-1001.
62. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-67.
63. Mars LT, Araujo L, Kerschen P, et al. Invariant NKT cells inhibit development of the Th17 lineage. Proc Natl Acad Sci USA 2009; 106: 6238-43.
64. Yang LJ. Big mac attack: does it play a direct role for monocytes/macrophages in type 1 diabetes? Diabetes 2008; 57: 2922-3.
65. Fletcher MT, Baxter AG. Clinical application of NKT cell biology in type I (autoimmune) diabetes mellitus. Immunol Cell Biol 2009; 87: 315-23.
66. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009; 9: 4-14.
67. Kis J, Engelmann P, Farkas K, et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2007; 81: 654-62.
68. Wilson SB, Kent SC, Patton KT, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391: 177-81.
69. Oikawa Y, Shimada A, Yamada S, et al. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care 2002; 25: 1818-23.
70. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110: 793-800.
71. Tsutsumi Y, Jie X, Ihara K, et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. Diabet Med 2006; 23: 1145-50.
72. Oling V, Marttila J, Knip M, Simell O, Ilonen J. Circulating CD4+CD25 high regulatory T cells and natural killer T cells in children with newly diagnosed type 1 diabetes or with diabetes-associated autoantibodies. Ann N Y Acad Sci 2007; 1107: 363-72.
73. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7: 727-38.
74. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-85.
75. Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46: 572-82.
76. Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. J Autoimmun 1997; 10: 279-85.
77. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26: 2989-98.
78. Wagner MJ, Hussain S, Mehan M, Verdi JM, Delovitch TL. A defect in lineage fate decision during fetal thymic invariant NKT cell development may regulate susceptibility to type 1 diabetes. J Immunol 2005; 174: 6764-71.
79. Hammond KJ, Pellicci DG, Poulton LD, et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001; 167: 1164-73.
80. Rocha-Campos AC, Melki R, Zhu R, et al. Genetic and functional analysis of the Nkt1 locus using congenic NOD mice: improved Valpha14-NKT cell performance but failure to protect against type 1 diabetes. Diabetes 2006; 55: 1163-70.
81. Fletcher JM, Jordan MA, Snelgrove SL, et al. Congenic analysis of the NKT cell control gene Nkt2 implicates the peroxisomal protein Pxmp4. J Immunol 2008; 181: 3400-12.
82. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002; 17: 725-36.
83. Cain JA, Smith JA, Ondr JK, Wang B, Katz JD. NKT cells and IFN-gamma establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J Immunol 2006; 176: 1645-54.
84. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. alpha/beta-T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187: 1047-56.
85. Lehuen A, Lantz O, Beaudoin L, et al. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188: 1831-9.
86. Laloux V, Beaudoin L, Jeske D, Carnaud C, Lehuen A. NK T cell- induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J Immunol 2001; 166: 3749-56.
87. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052-6.
88. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194: 313-20.
89. Shi FD, Flodstrom M, Balasa B, et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001; 98: 6777-82.
90. Alyanakian MA, Grela F, Aumeunier A, et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 2006; 55: 179-85.
91. Cardell S, Tangri S, Chan S, Kronenberg M, Benoist C, Mathis D. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med 1995; 182: 993-1004.
92. Naumov YN, Bahjat KS, Gausling R, et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001; 98: 13838-43.
93. Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7: 1057-62.
94. Forestier C, Takaki T, Molano A, et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J Immunol 2007; 178: 1415-25.
95. Mi QS, Ly D, Zucker P, McGarry M, Delovitch TL. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. Diabetes 2004; 53: 1303-10.
96. Chen YG, Choisy-Rossi CM, Holl TM, et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005; 174: 1196-204.
97. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006; 177: 3695-704.
98. Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58: 1302-11.
99. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164: 4375-81.
100. van der Vliet HJ, von Blomberg BM, Nishi N, et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100: 144-8.
101. Demoulins T, Gachelin G, Bequet D, Dormont D. A biased Valpha24+ T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. Immunol Lett 2003; 90: 223-8.
102. Parekh VV, Singh AK, Wilson MT, et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 2004; 173: 3693-706.
103. Singh AK, Wilson MT, Hong S, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1801-11.
104. Yoshimoto T, Bendelac A, Hu-Li J, Paul WE. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci USA 1995; 92: 11931-4.
105. Mars LT, Gautron AS, Novak J, et al. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 2008; 181: 2321-9.
106. Mars LT, Laloux V, Goude K, et al. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002; 168: 6007-11.
107. Teige A, Teige I, Lavasani S, et al. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J Immunol 2004; 172: 186-94.
108. Furlan R, Bergami A, Cantarella D, et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol 2003; 33: 1830-8.
109. Singh AK, Yang JQ, Parekh VV, et al. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane- induced lupus in mice. Eur J Immunol 2005; 35: 1143-54.
110. Jahng AW, Maricic I, Pedersen B, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1789-99.
111. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-4.
112. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
113. Miellot A, Zhu R, Diem S, Boissier MC, Herbelin A, Bessis N. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 2005; 35: 3704-13.
114. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44: 1127-38.
115. Linsen L, Thewissen M, Baeten K, et al. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R493-502.
116. Maeda T, Keino H, Asahara H, Taniguchi M, Nishioka K, Sumida T. Decreased TCR AV24AJ18+ double-negative T cells in rheumatoid synovium. Rheumatology (Oxford) 1999; 38: 186-8.
117. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999; 286: 1732-5.
118. Coppieters K, Dewint P, Van Beneden K, et al. NKT cells: manipulable managers of joint inflammation. Rheumatology (Oxford) 2007; 46: 565-71.
119. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum 2005; 52: 1941-8.
120. Ohnishi Y, Tsutsumi A, Goto D, et al. TCR Valpha14 natural killer T cells function as effector T cells in mice with collagen-induced arthritis. Clin Exp Immunol 2005; 141: 47-53.
121. Kim HY, Kim HJ, Min HS, et al. NKT cells promote antibody- induced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med 2005; 201: 41-7.
122. Coppieters K, Van Beneden K, Jacques P, et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol 2007; 179: 2300-9.
123. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha- galactosylceramide. Arthritis Rheum 2004; 50: 305-13.
124. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
125. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
126. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
127. Oishi Y, Sumida T, Sakamoto A, et al. Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 275-83.
128. Wither J, Cai YC, Lim S, et al. Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. Arthritis Res Ther 2008; 10: R108.
129. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003; 171: 4439-46.
130. Forestier C, Molano A, Im JS, et al. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice. J Immunol 2005; 175: 763-70.
131. Yang L, Jhaveri R, Huang J, Qi Y, Diehl A. Endoplasmic reticulum stress, hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Lab Invest 2007 2007; 87: 927-37.
132. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003; 112: 1211-22.
133. Yang JQ, Wen X, Liu H, et al. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum 2007; 56: 1219-33.
134. Morshed SR, Mannoor K, Halder RC, et al. Tissue-specific expansion of NKT and CD5+B cells at the onset of autoimmune disease in (NZBxNZW)F1 mice. Eur J Immunol 2002; 32: 2551-61.
135. Tsukamoto K, Ohtsuji M, Shiroiwa W, et al. Aberrant genetic control of invariant TCR-bearing NKT cell function in New Zealand mouse strains: possible involvement in systemic lupus erythematosus pathogenesis. J Immunol 2008; 180: 4530-9.
136. Matsuki N, Stanic AK, Embers ME, Van Kaer L, Morel L, Joyce S. Genetic dissection of V alpha 14J alpha 18 natural T cell number and function in autoimmune-prone mice. J Immunol 2003; 170: 5429-37.
137. Yang JQ, Singh AK, Wilson MT, et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003; 171: 2142-53.
138. Yang JQ, Chun T, Liu H, et al. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004; 34: 1723-32.
139. Sireci G, Russo D, Dieli F, et al. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol 2007; 37: 425-33.
140. Chan OT, Paliwal V, McNiff JM, Park SH, Bendelac A, Shlomchik MJ. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level. J Immunol 2001; 167: 2985-90.
141. Takahashi T, Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol 2008; 38: 156-65.
142. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 519-25.
143. Joyce S, Van Kaer L. Invariant natural killer T cells trigger adaptive lymphocytes to churn up bile. Cell Host Microbe 2008; 3: 275-7.
144. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525-9.
145. Oertelt S, Lian ZX, Cheng CM, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177: 1655-60.
146. Chuang YH, Lian ZX, Yang GX, et al. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 2008; 47: 571-80.
147. Chuang YH, Lian ZX, Tsuneyama K, et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 2006; 26: 232-40.
148. Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123: 1031-43.
149. Hirschfield GM, Liu X, Xu C, et al. Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants. N Engl J Med 2009; 360(24): 2544-55
150. Reinhardt C, Melms A. Elevated frequencies of natural killer T lymphocytes in myasthenia gravis. Neurology 1999; 52: 1485-7.
151. Suzuki Y, Onodera H, Tago H, et al. Altered populations of natural killer cell and natural killer T cell subclasses in myasthenia gravis. J Neuroimmunol 2005; 167: 186-9.
152. Nagane Y, Utsugisawa K, Obara D, Tohgi H. NKT-associated markers and perforin in hyperplastic thymuses from patients with Myasthenia gravis. Muscle Nerve 2001; 24: 1359-64.
153. Shi FD, Wang HB, Li H, et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000; 1: 245-51.
154. Liu R, La Cava A, Bai XF, et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005; 175: 7898-904.
155. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205: 799-810.
156. Grajewski RS, Hansen AM, Agarwal RK, et al. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol 2008; 181: 4791-7.
157. Watanabe M, Nakamura Y, Matsuzuka F, Takamura Y, Miyauchi A, Iwatani Y. Decrease of intrathyroidal CD161+Valpha24+Vbeta11+ NKT cells in Graves' disease. Endocr J 2008; 55: 199-203.
158. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol 2004; 173: 2167-73.
159. Rowley B, Monestier M. Mechanisms of heavy metal-induced autoimmunity. Mol Immunol 2005; 42: 833-8.
160. Vas J, Mattner J, Richardson S, et al. Regulatory roles for NKT cell ligands in environmentally induced autoimmunity. J Immunol 2008; 181: 6779-88.
161. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008; 58: 734-43.
162. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008; 181: 2898-906.
163. Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008; 50: 240-2.
164. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
165. Motohashi S, Nagato K, Kunii N, et al. A phase I-II study of alpha- galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non- small cell lung cancer. J Immunol 2009; 182: 2492-501.
166. Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006; 12: 6079-86.
167. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11: 1910-7.
168. Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103: 383-9.
169. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702-9.
170. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha- galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201: 1503-17.
171. Uchida T, Horiguchi S, Tanaka Y, et al. Phase I study of alpha- galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57: 337-45.
172. Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 2007; 47: 356-65.
173. Biburger M, Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol 2005; 175: 1540-50.
174. Fujii H, Seki S, Kobayashi S, et al. A murine model of NKT cell- mediated liver injury induced by alpha-galactosylceramide/d- galactosamine. Virchows Arch 2005; 446: 663-73.
175. Osman Y, Kawamura T, Naito T, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha- galactosylceramide. Eur J Immunol 2000; 30: 1919-28.
176. Ito K, Karasawa M, Kawano T, et al. Involvement of decidual Valpha14 NKT cells in abortion. Proc Natl Acad Sci USA 2000; 97: 740-4.
177. Major A, Singh R, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res 2006; 34: 49-66.
178. Nakai Y, Iwabuchi K, Fujii S, et al. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104: 2051-9.
179. Major AS, Wilson MT, McCaleb JL, et al. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2351-7.
180. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002; 2: 557-68.
181. Hammond KJ, Godfrey DI. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens 2002; 59: 353-63.
182. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003; 3: 211-22.
183. Thapa P, Zhang G, Xia C, et al. Nanoparticle formulated alpha- galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009; 27: 3484-8.
184. Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J Immunol 2001; 166: 662-8.